NO2222861T3 - - Google Patents

Info

Publication number
NO2222861T3
NO2222861T3 NO08859393A NO08859393A NO2222861T3 NO 2222861 T3 NO2222861 T3 NO 2222861T3 NO 08859393 A NO08859393 A NO 08859393A NO 08859393 A NO08859393 A NO 08859393A NO 2222861 T3 NO2222861 T3 NO 2222861T3
Authority
NO
Norway
Application number
NO08859393A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2222861T3 publication Critical patent/NO2222861T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/108Plasmid DNA episomal vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/24Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Artificial Filaments (AREA)
NO08859393A 2007-12-11 2008-12-11 NO2222861T3 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US711807P 2007-12-11 2007-12-11
PCT/US2008/086409 WO2009076524A2 (en) 2007-12-11 2008-12-11 Polypurine tract modified retroviral vectors

Publications (1)

Publication Number Publication Date
NO2222861T3 true NO2222861T3 (enExample) 2018-05-05

Family

ID=40756119

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08859393A NO2222861T3 (enExample) 2007-12-11 2008-12-11

Country Status (16)

Country Link
US (2) US9796987B2 (enExample)
EP (2) EP2222861B1 (enExample)
JP (2) JP5749014B2 (enExample)
CY (1) CY1119905T1 (enExample)
DK (1) DK2222861T3 (enExample)
ES (1) ES2664988T3 (enExample)
HR (1) HRP20180184T1 (enExample)
HU (1) HUE036103T2 (enExample)
LT (1) LT2222861T (enExample)
NO (1) NO2222861T3 (enExample)
PL (1) PL2222861T3 (enExample)
PT (1) PT2222861T (enExample)
RS (1) RS56844B1 (enExample)
SI (1) SI2222861T1 (enExample)
TR (1) TR201802323T4 (enExample)
WO (1) WO2009076524A2 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006252406B2 (en) 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
SG173337A1 (en) 2006-07-21 2011-08-29 California Inst Of Techn Targeted gene delivery for dendritic cell vaccination
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom
WO2011011584A1 (en) * 2009-07-24 2011-01-27 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
SG192759A1 (en) 2011-02-15 2013-09-30 Immune Design Corp Methods for enhancing immunogen specific immune responses by vectored vaccines
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
EP2831095B1 (en) 2012-03-30 2018-11-28 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
LT2850431T (lt) 2012-05-16 2018-06-25 Immune Design Corp. Vakcinos, skirtos hsv-2
CA2939093A1 (en) 2014-02-14 2015-08-20 Immune Design Corp. Immunotherapy of cancer through combination of local and systemic immune stimulation
KR20170032373A (ko) 2014-07-15 2017-03-22 이뮨 디자인 코포레이션 Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법
KR101607282B1 (ko) 2014-12-18 2016-03-29 충남대학교산학협력단 유리형 산화환원조절단백-1 및 이를 함유하는 항염증 약학조성물
JP6734283B2 (ja) 2015-01-21 2020-08-05 フレッド ハッチンソン キャンサー リサーチ センター 遺伝子治療用ポイントオブケア及び/又はポータブルプラットフォーム
US11078495B2 (en) 2015-10-15 2021-08-03 The University Of North Carolina At Chapel Hill Methods and compositions for integration defective lentiviral vectors
KR20180108567A (ko) 2015-10-22 2018-10-04 주노 테라퓨틱스 게엠베하 형질도입을 위한 방법, 키트, 제제 및 장치
CA3004132A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
MX2018005467A (es) 2015-11-09 2018-12-11 Immune Design Corp Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas.
MX2018010061A (es) 2016-02-23 2019-07-04 Immune Design Corp Preparaciones de vectores retrovirales de genomas multiples, y metodos y sistemas para producir y usar las mismas.
EP3443000B1 (en) 2016-04-15 2025-11-12 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
KR102824067B1 (ko) 2016-04-15 2025-06-23 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11421287B2 (en) 2016-07-29 2022-08-23 Juno Therapeutics, Inc. Methods for assessing the presence or absence of replication competent virus
CN110249046A (zh) 2016-12-05 2019-09-17 朱诺治疗学股份有限公司 用于过继细胞疗法的工程化细胞的产生
LT3596116T (lt) 2017-03-16 2023-11-10 Alpine Immune Sciences, Inc. Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
CA3054068A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
MX2020000900A (es) 2017-07-29 2021-01-08 Juno Therapeutics Inc Reactivos para expandir celulas que expresan receptores recombinantes.
CA3070579A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
MX2020004540A (es) 2017-10-18 2020-08-03 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
WO2019089855A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
JP7258899B2 (ja) 2017-11-01 2023-04-17 ジュノー セラピューティクス インコーポレイテッド T細胞組成物を作製するための方法
KR102833956B1 (ko) 2017-12-08 2025-07-15 주노 쎄러퓨티크스 인코퍼레이티드 세포를 배양하기 위한 무혈청 배지 제형 및 이의 사용 방법
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
EP3746569A1 (en) 2018-01-31 2020-12-09 Juno Therapeutics, Inc. Methods and reagents for assessing the presence or absence of replication competent virus
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN113544144A (zh) 2018-09-19 2021-10-22 高山免疫科学股份有限公司 变体cd80融合蛋白和相关构建体的方法和用途
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CA3120118A1 (en) 2018-11-16 2020-05-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
IL283298B2 (en) 2018-11-30 2025-03-01 Juno Therapeutics Inc Methods for dosing and treating B-cell malignancies with adoptive cell therapy
WO2020113194A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
AU2020257238A1 (en) 2019-04-17 2021-12-02 Alpine Immune Sciences, Inc. Methods and uses of variant ICOS Ligand (ICOSL) fusion proteins
AU2020287882A1 (en) 2019-06-07 2022-01-20 Juno Therapeutics, Inc. Automated T cell culture
MA56206A (fr) 2019-06-12 2022-04-20 Juno Therapeutics Inc Combinaison thérapeutique d'une thérapie cytotoxique à médiation cellulaire et d'un inhibiteur d'une protéine de la famille bcl2 pro-survie
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド T細胞療法とzesteホモログ2エンハンサー(EZH2)阻害剤との併用療法および関連方法
EP4055383A1 (en) 2019-11-05 2022-09-14 Juno Therapeutics, Inc. Methods of determining attributes of therapeutic t cell compositions
AU2020395318A1 (en) 2019-12-06 2022-06-09 Juno Therapeutics, Inc. Methods related to toxicity and response associated with cell therapy for treating B cell malignancies
MX2022009041A (es) 2020-01-24 2022-10-07 Juno Therapeutics Inc Metodos de dosificacion y tratamiento de linfoma folicular y linfoma de zona marginal en terapia celular adoptiva.
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 형질도입 방법
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
CN115812077A (zh) 2020-05-08 2023-03-17 高山免疫科学股份有限公司 April和baff抑制性免疫调节蛋白及其使用方法
JP7727662B2 (ja) 2020-05-13 2025-08-21 ジュノー セラピューティクス インコーポレイテッド 臨床応答に関連する特徴量の特定方法およびその使用
CA3197730A1 (en) 2020-10-15 2022-04-21 F. Hoffman-La Roche Ag Nucleic acid constructs for va rna transcription
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
CA3210581A1 (en) 2021-03-22 2022-09-29 Neil HAIG Methods of determining potency of a therapeutic cell composition
AU2022244229A1 (en) 2021-03-22 2023-09-14 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
KR20240005700A (ko) 2021-03-29 2024-01-12 주노 쎄러퓨티크스 인코퍼레이티드 체크포인트 억제제 요법 및 car t 세포 요법의 조합을 사용한 투여 및 치료 방법
WO2022236335A1 (en) 2021-05-07 2022-11-10 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
US20250059560A1 (en) 2021-12-16 2025-02-20 Sana Biotechnology, Inc. Methods and systems of particle production
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
JP2025521543A (ja) 2022-06-22 2025-07-10 ジュノー セラピューティクス インコーポレイテッド Cd19標的car t細胞のセカンドライン治療のための処置方法
EP4598557A2 (en) 2022-10-04 2025-08-13 Alpine Immune Sciences, Inc. Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
WO2024263991A2 (en) * 2023-06-22 2024-12-26 Arc Research Institute Methods and compositions for integration deficient viral vectors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
CN100390291C (zh) 1995-11-28 2008-05-28 约翰斯·霍普金斯大学医学院 条件复制型病毒载体及其用法
AU1100201A (en) 1999-10-28 2001-05-08 Board Of Trustees Of The Leland Stanford Junior University Methods of in vivo gene transfer using a sleeping beauty transposon system
US6673567B2 (en) 2000-03-23 2004-01-06 E. I. Du Pont De Nemours And Company Method of determination of gene function
US20030003565A1 (en) * 2000-11-27 2003-01-02 Dubensky Thomas W. Functional lentiviral vector from an MLV-based backbone
EP1534847B1 (en) 2002-09-03 2015-10-28 Oxford Biomedica (UK) Limited Retroviral vector and stable packaging cell lines
US7220578B2 (en) 2002-11-27 2007-05-22 Tal Kafri Single LTR lentivirus vector
WO2005023313A1 (en) * 2003-09-09 2005-03-17 Virxsys Corporation Lentivirus vector-based approaches for generating an immune response to hiv humans
GB0325379D0 (en) 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
WO2005056057A1 (en) * 2003-12-04 2005-06-23 Childrens Hospital Los Angeles Research Institute Minimal lentiviral vector system
US20070048285A1 (en) * 2005-08-24 2007-03-01 Christopher Baum Self-inactivating retroviral vector
EP1757703A3 (en) 2005-08-24 2007-12-05 Medizinische Hochschule Hannover Self-inactivating retroviral vector
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom

Also Published As

Publication number Publication date
CY1119905T1 (el) 2018-06-27
SI2222861T1 (en) 2018-04-30
JP2011505835A (ja) 2011-03-03
TR201802323T4 (tr) 2018-03-21
HUE036103T2 (hu) 2018-06-28
EP2222861B1 (en) 2017-12-06
EP3342872A1 (en) 2018-07-04
JP5749014B2 (ja) 2015-07-15
LT2222861T (lt) 2018-03-26
DK2222861T3 (en) 2018-02-05
US10017785B2 (en) 2018-07-10
EP2222861A2 (en) 2010-09-01
JP6001702B2 (ja) 2016-10-05
US20180119170A1 (en) 2018-05-03
US9796987B2 (en) 2017-10-24
EP2222861A4 (en) 2011-12-28
US20100323403A1 (en) 2010-12-23
JP2015119715A (ja) 2015-07-02
ES2664988T3 (es) 2018-04-24
WO2009076524A3 (en) 2009-09-11
PT2222861T (pt) 2018-02-16
PL2222861T3 (pl) 2018-04-30
HRP20180184T1 (hr) 2018-04-06
WO2009076524A2 (en) 2009-06-18
RS56844B1 (sr) 2018-04-30

Similar Documents

Publication Publication Date Title
NO2222861T3 (enExample)
BRPI0818327A2 (enExample)
CN300728292S (zh) 隐形纱窗纱门用纱盒
CN300729624S (zh) 感应垃圾桶(dzt-42-18)
CN300730152S (zh) 汽油机箱体
CN300730102S (zh) 室内天线(uvr-av234)
CN300730063S (zh) 显示器(ul-1931w)
CN300727217S (zh) 多功能电子计步器
CN300727421S (zh) 轮椅电力驱动装置
CN300729279S (zh) 气动扳手(89700一英寸)
CN300729237S (zh) 多用刀
CN300727232S (zh) 入侵探测器
CN300730011S (zh) 收录放音机(gh-643)
CN300726028S (zh) 鞋底
CN300726082S (zh) 钥匙扣(钻石形)
CN300726085S (zh) 眼镜盒(带台灯)
CN300726214S (zh) 布(27)
CN300726221S (zh) 面料(欧根沙)
CN300726239S (zh) 包装纸(四)
CN300726336S (zh) 沙发(主人位s-19)
CN300726480S (zh) 视听柜(k203)
CN300726907S (zh) 包装盒
CN300727142S (zh) 包装袋(稗申)
CN300727177S (zh) 包装袋(jmy-003)
CN300729081S (zh) 碗(旋涡)